GSK seeks FDA approval for Nuvalent-acquired lung cancer therapy after strong trial results
GSK plans to submit its recently acquired drug Jideytro to the FDA after trial data showed a 94% response rate in first-line treatment for ROS1-positive non-small cell lung cancer. The results were presented at the World Conference on Lung Cancer over the weekend. The drug was originally developed by Nuvalent.
GSK is advancing Jideytro toward a regulatory filing with the FDA, following encouraging trial outcomes presented at the World Conference on Lung Cancer. The therapy, which came to GSK through its acquisition of Nuvalent, produced a 94% response rate when used as an initial treatment for patients with ROS1-positive non-small cell lung cancer.
This particular cancer subtype is defined by a specific genetic marker, making it a targeted patient group. The high response rate in the first-line setting positions Jideytro as a potentially significant option for these individuals, though FDA review will determine its ultimate availability. The submission also marks a notable milestone for GSK's expanding oncology pipeline.
If approved, Jideytro could meaningfully alter the treatment landscape for patients with ROS1-positive non-small cell lung cancer, a relatively uncommon but distinct population. A 94% first-line response rate may translate into longer disease control and improved quality of life for these individuals. However, regulatory scrutiny, pricing decisions, and insurance coverage will shape real-world access. Oncologists and patient advocacy groups may closely track the FDA's review timeline, as any new targeted therapy carries implications for clinical practice and patient outcomes.